Hospira, Inc. provides injectable drugs and infusion technologies to
develop, manufacture, distribute, and markets products worldwide. The
company offers specialty injectable pharmaceuticals, which include
approximately 200 injectable generic drugs in multiple dosages and
formulations; proprietary specialty injectables, including Precedex, a
proprietary drug for sedation; and Biosimilars that comprise Retacrit, a
biosimilar erythropoietin, which is primarily used in the treatment of
anemia in dialysis and in certain oncology applications, as well as
Nivestim, a biosimilar filgrastim used for the treatment of low white
blood cells in patients who have received a chemotherapeutic agent. It
also provides intravenous solutions and nutritional products; and
contract manufacturing services. In addition, the company offers
medication management products consisting of infusion pumps and
dedicated administration sets; Hospira MedNet safety software system and
related services; software applications and devices that support
point-of-care medication administration; gravity administration sets;
and other device products.
To review Hospira's stock, please take a look at the 1-year chart of HSP (Hospira, Inc.) below with my added notations:
HSP has been trading sideways for the last 5 months. Over that period
of time, the stock has formed a clear resistance level at $42 (red). In
addition, the stock has also created a strong level of support at $38
(blue) that has held since the beginning of July. At some point the
stock will have to break one of those two levels.
The Tale of the Tape: HSP has clear levels of
support ($38) and resistance ($42). The possible long positions on the
stock would be either on a pullback to $38, or on a breakout above $42.
The ideal short opportunity would be on a break below $38.
Please share this article
No comments:
Post a Comment